ANALYSIS OF CEA, CA19-9, CA72-4 AND HELICOBACTER PYLORI ANTIBODIES IN PATIENTS WITH GASTRIC CANCER_CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Authors：

Niu Weixin , Sheng Weizhong , Qin Xinyu.

Department of General Surgery, The Affiliated Zhongshan Hospital, Shanghai University of Medical Sciences, Shanghai 200032;

Corresponding author：

Keywords：

Carcinoembrynic antigen; Gastritic cancer; Helicobacter pylori

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Serum tumor markers CEA, CA19-9, CA72-4 and Helicobacter pylori (H.pylori) antibodies were measured in 162 patients with gastric cancer. CEA, CA19-9 and CA72-4 had sensitivities of 24.0%, 35.5% and 21.9% respectively. CA72-4 provided 100% specifity, compared to 77% and 93% for CA19-9 and CEA. The positive predictive value (PV) in CEA, CA19-9 and CA72-4 was higher than negative PV. Serum CA19-9 and CA72-4 levels rose in tumor of ＞5.0cm in diameter. The CA19-9 increased remarkably when the deeper stomach wall was invased. The significantly elevated CEA, CA72-4 and CA19-9 levels were found in patients who had nodal involvement in more than 50% and distant metastasis. However, the increase of CEA, CA19-9 and CA72-4 were found in undifferentiated tumor. Antibodies to H.pylori were detected in 54% of patients but in only 22% control subjects. A significant association was found between H.pylori infection and gastric cancer (odds ratio=3.75; 95% confidence interval=2.11-5.41, Ｐ＜0.01). Conclusions: CEA, CA19-9 and CA72-4 have higher specifity but lower sensitivity in diagnosis of the gastric cancer. The levels of CEA, CA19-9 and CA72-4 are significantly associated with the diameter, the depth of invasion, nodal involvement, distant metastasis and cell differention. Infection with H.pylori may be an important cause of gastric cancer.

Citation： Niu Weixin,Sheng Weizhong,Qin Xinyu.. ANALYSIS OF CEA, CA19-9, CA72-4 AND HELICOBACTER PYLORI ANTIBODIES IN PATIENTS WITH GASTRIC CANCER. CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY, 1999, 6(3): 162-165. doi: Copy

1.	Talley NJ, Zinsmeister AR, Weaver A, et al. Gastric adenocarcinoma and Helicobacter pylori infection. National Cancer Institute, 1991; 83(23)∶1734.
2.	Forman D, Newell DG, Fullerton F, et al. Association between infection with Helicobacter pylori and risk of gastric cacner: evidence from a prospective investigation. BMJ, 1991; 302(1)∶1302.
3.	Gold P, Freedman SO. Specific carcinoembryonic antigens of the human digestive system. J Exp Med, 1965; 122(3)∶467.
4.	Jalanko H, Kuusela P, Roberts P, et al. Comparison of a new tumour marker, CA199 TM, with AFP and CEA in patients with upper gasrointestinal diseases. J Clin Pathol, 1984; 37(2)∶218.
5.	Quentmeier A, Schlag P, Geisen HP, et al. Evaluation of CA125 as a tumor marker for gastric and colorectal cancer in comparison to CEA and CA199. Eur J Surg Oncol, 1987; 13(3)∶197.
6.	Joypaul B, Browning M, Newman E, et al. Comparison of serum CA724 and CA199 levels in gastric cancer patients and correlation with recurrence. Am J Surg, 1995; 169(6)∶595.
7.	Shimizu N, Wakatsuki T, Murakami A, et al. Carcinoembryonic antigen in gastric cancer patients. Oncol, 1987; 44(4)∶240.
8.	Ikeda Y, Oomori H, Koyanagi N, et al. Prognostic value of combination assays for CEA and CA199 in gastric cancer. Oncol, 1995 ; 52(6)∶483.
9.	Maeta M, Yoshioka H, Shimizu T, et al. Carbohydrate antigen CA199 in tissues and sera from patients with gastric cancer. Oncol, 1990; 47(3)∶229.
10.	Kornek G, Depisch D, Temsch EM, et al. Comparative analysis of cancerassociated antigen CA195, CA199 and CEA in diagnosis, followup and monitoring of response to chemotherapy in patients with gastrointestinal cancer. J Cancer Res Clin Oncol, 1991; 117(5)∶493.
11.	Gupta M, Arciaga R, Bocci L, et al. Measurement of a monoclonalantibodydefined antigen (CA199) in the sera of patients with maliganant and nonmaliganat diseases. Cancer, 1985; 56(2)∶277.
12.	Nomura A, Stemmermann G, Chyou P, et al. Helicobacter pylori infection and gastric carcinoma among Japanese Americans in Hawaii. New Engl J Med, 1991; 325(16)∶1132.
13.	Parsonnet J Friedman GD, Vandersteen DP, et al. Helicobacter pylori infection and the risk of gastric carcinoma. New Engl J Med, 1991; 325(16)∶1127.
14.	Blaser M, PerezPerez GI, Kleanthous H, et al. Infection with Helicobacter pylori strains possessing CagA is associated with an increased risk of developing adenocarcinoma of the stomach. Cancer Res, 1995; 55(10)∶2111.
15.	The Eurogast Study Group. An international association between Helicobacter pylori infection and gastric cancer. Lancet, 1993; 341(8857)∶1359.
16.	Kikuchi S, Wada O, Nakajima T, et al. Serum antiHelicobacter pylori antibody and gastric carcinoma among young adults. Cancer, 1995; 75(12)∶2789.

1. Talley NJ, Zinsmeister AR, Weaver A, et al. Gastric adenocarcinoma and Helicobacter pylori infection. National Cancer Institute, 1991; 83(23)∶1734.
2. Forman D, Newell DG, Fullerton F, et al. Association between infection with Helicobacter pylori and risk of gastric cacner: evidence from a prospective investigation. BMJ, 1991; 302(1)∶1302.
3. Gold P, Freedman SO. Specific carcinoembryonic antigens of the human digestive system. J Exp Med, 1965; 122(3)∶467.
4. Jalanko H, Kuusela P, Roberts P, et al. Comparison of a new tumour marker, CA199 TM, with AFP and CEA in patients with upper gasrointestinal diseases. J Clin Pathol, 1984; 37(2)∶218.
5. Quentmeier A, Schlag P, Geisen HP, et al. Evaluation of CA125 as a tumor marker for gastric and colorectal cancer in comparison to CEA and CA199. Eur J Surg Oncol, 1987; 13(3)∶197.
6. Joypaul B, Browning M, Newman E, et al. Comparison of serum CA724 and CA199 levels in gastric cancer patients and correlation with recurrence. Am J Surg, 1995; 169(6)∶595.
7. Shimizu N, Wakatsuki T, Murakami A, et al. Carcinoembryonic antigen in gastric cancer patients. Oncol, 1987; 44(4)∶240.
8. Ikeda Y, Oomori H, Koyanagi N, et al. Prognostic value of combination assays for CEA and CA199 in gastric cancer. Oncol, 1995 ; 52(6)∶483.
9. Maeta M, Yoshioka H, Shimizu T, et al. Carbohydrate antigen CA199 in tissues and sera from patients with gastric cancer. Oncol, 1990; 47(3)∶229.
10. Kornek G, Depisch D, Temsch EM, et al. Comparative analysis of cancerassociated antigen CA195, CA199 and CEA in diagnosis, followup and monitoring of response to chemotherapy in patients with gastrointestinal cancer. J Cancer Res Clin Oncol, 1991; 117(5)∶493.
11. Gupta M, Arciaga R, Bocci L, et al. Measurement of a monoclonalantibodydefined antigen (CA199) in the sera of patients with maliganant and nonmaliganat diseases. Cancer, 1985; 56(2)∶277.
12. Nomura A, Stemmermann G, Chyou P, et al. Helicobacter pylori infection and gastric carcinoma among Japanese Americans in Hawaii. New Engl J Med, 1991; 325(16)∶1132.
13. Parsonnet J Friedman GD, Vandersteen DP, et al. Helicobacter pylori infection and the risk of gastric carcinoma. New Engl J Med, 1991; 325(16)∶1127.
14. Blaser M, PerezPerez GI, Kleanthous H, et al. Infection with Helicobacter pylori strains possessing CagA is associated with an increased risk of developing adenocarcinoma of the stomach. Cancer Res, 1995; 55(10)∶2111.
15. The Eurogast Study Group. An international association between Helicobacter pylori infection and gastric cancer. Lancet, 1993; 341(8857)∶1359.
16. Kikuchi S, Wada O, Nakajima T, et al. Serum antiHelicobacter pylori antibody and gastric carcinoma among young adults. Cancer, 1995; 75(12)∶2789.

CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

ANALYSIS OF CEA, CA19-9, CA72-4 AND HELICOBACTER PYLORI ANTIBODIES IN PATIENTS WITH GASTRIC CANCER

Abstract Full text Figures/Tables Video References Cited by

Format

Content